Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.
DeNardo
Gerald L
GL
Department of Internal Medicine, University of California, Davis, Sacramento, CA 95816, USA. gldenardo@ucdavis.edu
DeNardo
Sally J
SJ
Balhorn
Rod
R
D000818:Animals; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D004307:Dose-Response Relationship, Radiation; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy / Q000628:therapy; D009369:Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods*; D011879:Radiotherapy Dosage; D016879:Salvage Therapy / Q000379:methods
D011838:Radiation-Sensitizing Agents
Cancer Biother Radiopharm. 1998 Aug;13(4):239-54
10850360
Clin Cancer Res. 1997 Sep;3(9):1547-55
9815842
Cancer Biother Radiopharm. 2001 Aug;16(4):305-15
11603001
Clin Cancer Res. 2004 Dec 1;10(23):7792-8
15585610
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
2032882
J Nucl Med. 2007 Aug;48(8):1357-68
17631548
J Nucl Med. 1997 Aug;38(8):1180-5
9255145
J Nucl Med. 2005 Jan;46 Suppl 1:67S-75S
15653654
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21
14506163
Clin Cancer Res. 2001 Jan;7(1):175-84
11205906
Blood. 2002 Jun 15;99(12):4336-42
12036859
J Clin Oncol. 2004 Sep 1;22(17):3593-607
15337810
J Nucl Med. 2003 Mar;44(3):400-11
12621007
Cancer Biother Radiopharm. 2007 Aug;22(4):453-68
17803440
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1802-7
10677537
Cancer Biother Radiopharm. 2008 Dec;23(6):783-96
20443696
Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S46-56
16979440
Blood. 2004 Jun 15;103(12):4429-31
15016644
J Nucl Med. 2003 Mar;44(3):465-74
12621016
J Clin Oncol. 1998 Oct;16(10):3246-56
9779698
Methods Mol Biol. 2004;248:209-25
14970499
Blood. 2006 Jul 1;108(1):328-36
16556891
J Endocrinol Invest. 2005;28(11 Suppl International):146-50
16625865
Cancer Res. 1995 Dec 1;55(23 Suppl):5921s-5924s
7493371
Cancer. 1994 Feb 1;73(3 Suppl):1023-32
8306244
J Clin Oncol. 1998 Oct;16(10):3270-8
9779701
J Clin Oncol. 2001 Oct 1;19(19):3918-28
11579112
Curr Probl Cancer. 2002 May-Jun;26(3):109-64
12085086
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4000-4
9108094
J Clin Oncol. 2005 Oct 20;23(30):7565-73
16186600
N Engl J Med. 2005 Feb 3;352(5):441-9
15689582
J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S
15653647
Bioconjug Chem. 2007 May-Jun;18(3):912-21
17373772
Blood. 2002 May 1;99(9):3158-62
11964278
J Nucl Med. 1992 Sep;33(9):1648-53
1517839
Cancer Biother Radiopharm. 2007 Oct;22(5):573-84
17979560
Lancet. 1995 Aug 5;346(8971):336-40
7623531
Proc Natl Acad Sci U S A. 2006 May 2;103(18):6841-6
16636283
Blood. 2003 Oct 1;102(7):2351-7
12750161
Cancer. 1997 Dec 15;80(12 Suppl):2583-90
9406713
Int J Oncol. 2007 Oct;31(4):729-40
17786303
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5621s-5628s
17875798
Semin Oncol. 2005 Feb;32(1 Suppl 1):S27-35
15786023
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7075s-7079s
16203805
J Natl Cancer Inst. 1990 May 2;82(9):763-71
2182892
Blood. 2000 Nov 1;96(9):2934-42
11049969
Blood. 2008 Feb 15;111(4):2261-8
18042793
Blood. 2001 Oct 15;98(8):2535-43
11588052
Semin Nucl Med. 2006 Apr;36(2):147-56
16517236
J Nucl Med. 2006 Aug;47(8):1238-40
16882999
J Clin Oncol. 2002 May 15;20(10):2453-63
12011122
Endocr Relat Cancer. 2004 Dec;11(4):689-708
15613446
Blood. 2003 Sep 1;102(5):1606-12
12738671
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
7612182
Cancer Biother Radiopharm. 2005 Apr;20(2):185-8
15869453
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s
16203810
Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45
18773247
Update Cancer Ther. 2007 Mar;2(1):19-31
18311322
J Clin Oncol. 2002 Aug 1;20(15):3262-9
12149300
J Nucl Med. 2008 Jan;49(1):158-63
18077530
J Radiat Res. 2005 Jun;46(2):241-8
15988143
Cancer. 2002 Feb 15;94(4 Suppl):1332-48
11877764
J Clin Oncol. 2005 Sep 20;23(27):6763-70
16170184
Eur J Nucl Med. 1999 Feb;26(2):110-20
9933344
Clin Cancer Res. 1999 Oct;5(10 Suppl):3243s-3248s
10541370
J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S
15653661
Clin Lymphoma. 2000 Jun;1(1):46-54
11707813
Blood. 2004 Jul 1;104(1):227-36
14996706
Blood. 2000 Aug 15;96(4):1259-66
10942366
Cancer Biother Radiopharm. 2000 Feb;15(1):15-29
10740649
J Nucl Med. 2008 Apr;49(4):674-8
18344431
J Immunol. 1985 Dec;135(6):3795-801
2415587
Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):478-85
15655678
Blood. 2003 Mar 15;101(6):2340-8
12446461
Cancer Biother Radiopharm. 2006 Dec;21(6):645-54
17257080
J Clin Oncol. 2006 Feb 10;24(5):823-34
16380412
J Clin Oncol. 2006 Apr 10;24(11):1705-11
16549819
Clin Cancer Res. 1999 Oct;5(10 Suppl):3224s-3231s
10541368
J Nucl Med. 2001 Feb;42(2):213-21
11216519